Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial
- PMID: 12807337
- DOI: 10.1078/1433-187x-00308
Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial
Abstract
Background: New evidence-based treatment options are required to avoid antibiotic overuse in acute bronchitis and to replace potentially inefficacious initial antibiotic treatment.
Objective: To evaluate the efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) compared to placebo in patients with acute bronchitis.
Design: Randomized, double-blind, placebo-controlled trial using a multi-stage adaptive design.
Setting: 36 primary care physicians (investigators) at the out-patient care setting.
Patients: 468 adults with acute bronchitis present < or = 48 hours, Bronchitis Severity Score (BSS) > or = 5 points, and informed consent.
Intervention: EPs 7630 or placebo (30 drops three times daily) for 7 days.
Measurement: The primary outcome criterion was the change of BSS on day 7.
Results: The decrease of BSS from baseline to day 7 was 5.9 +/- 2.9 points under EPs 7630 (n = 233), and 3.2 +/- 4.1 points under placebo (n = 235). The 95% CI for the difference of effects between the two treatment groups (EPs 7630 minus placebo) was calculated as [-3.359; -2.060] showing a significant superiority of EPs 7630 compared to placebo on day 7 (p < 0.0001). Working inability decreased to 16% in the EPs 7630 group compared to 43% in the placebo group (p < 0.0001). In addition, the duration of illness was significantly shorter for patients treated with EPs 7630 compared to placebo (p < 0.001). Within the first four days, onset of treatment effect was recognized in 53.6% of patients under EPs 7630 compared to 36.2% of patients under placebo, only (p < 0.0001). Adverse events (AEs) occurred in 36/468 patients (EPs 7630: 20/233 patients, placebo: 16/235 patients). All events were assessed as non-serious.
Conclusion: EPs 7630 was superior in efficacy compared to placebo in the treatment of adults with acute bronchitis. Treatment with EPs 7630 clearly reduced the severity of symptoms and shortened the duration of working inability for nearly 2 days.
Similar articles
-
Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial.Explore (NY). 2005 Nov;1(6):437-45. doi: 10.1016/j.explore.2005.08.009. Explore (NY). 2005. PMID: 16781588 Clinical Trial.
-
Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study.Curr Med Res Opin. 2007 Feb;23(2):323-31. doi: 10.1185/030079906X167318. Curr Med Res Opin. 2007. PMID: 17288687 Clinical Trial.
-
Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial.Explore (NY). 2007 Nov-Dec;3(6):573-84. doi: 10.1016/j.explore.2007.09.004. Explore (NY). 2007. PMID: 18005909 Clinical Trial.
-
Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis.Phytomedicine. 2008 May;15(5):378-85. doi: 10.1016/j.phymed.2007.11.023. Epub 2008 Jan 28. Phytomedicine. 2008. PMID: 18222667 Review.
-
Pelargonium sidoides extract for treating acute respiratory tract infections.Cochrane Database Syst Rev. 2013 Oct 22;(10):CD006323. doi: 10.1002/14651858.CD006323.pub3. Cochrane Database Syst Rev. 2013. PMID: 24146345 Review.
Cited by
-
Current state of research on the clinical benefits of herbal medicines for non-life-threatening ailments.Front Pharmacol. 2023 Sep 28;14:1234701. doi: 10.3389/fphar.2023.1234701. eCollection 2023. Front Pharmacol. 2023. PMID: 37841934 Free PMC article.
-
Pelargonium sidoides extract mediates nephrotoxicity through mitochondrial malfunction and cytoskeleton destabilization.Toxicol Res. 2023 May 27;39(4):601-609. doi: 10.1007/s43188-023-00186-0. eCollection 2023 Oct. Toxicol Res. 2023. PMID: 37779585
-
In vitro and in vivo effects of Pelargonium sidoides DC. root extract EPs® 7630 and selected constituents against SARS-CoV-2 B.1, Delta AY.4/AY.117 and Omicron BA.2.Front Pharmacol. 2023 Jul 26;14:1214351. doi: 10.3389/fphar.2023.1214351. eCollection 2023. Front Pharmacol. 2023. PMID: 37564181 Free PMC article.
-
Effects of EPs 7630 on the duration of inability to work in acute bronchitis - a meta-analysis.Multidiscip Respir Med. 2023 Jun 13;18(1):914. doi: 10.4081/mrm.2023.914. eCollection 2023 Jan 17. Multidiscip Respir Med. 2023. PMID: 37476531 Free PMC article.
-
Significant Broad-Spectrum Antiviral Activity of Bi121 against Different Variants of SARS-CoV-2.Viruses. 2023 May 31;15(6):1299. doi: 10.3390/v15061299. Viruses. 2023. PMID: 37376598 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical